Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives as KATP channel agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 20, 2002, Pages 2977-2980

  Peat, Andrew J ^a   Townsend, Claire ^a   Worley, III, Jennings F ^a   Allen, Scott H ^a   Garrido, Dulce ^a   Mertz, Robert J ^a   Pfohl, Jeffrey L ^a   Terry, Christopher M ^a   Truax, Jim F ^a   Veasey, Robert L ^a   Thomson, Stephen A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CYCLOBUTYLAMINO 4H BENZOTHIADIAZINE 1,1 DIOXIDE; ADENOSINE TRIPHOSPHATASE (POTASSIUM); BENZOTHIADIAZINE DERIVATIVE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; HORMONAL REGULATION; HYPERINSULINEMIA; INSULIN RELEASE; PANCREAS ISLET BETA CELL; PATCH CLAMP; SYNTHESIS;

ATP-BINDING CASSETTE TRANSPORTERS; BENZOTHIADIAZINES; ELECTRONS; ELECTROPHYSIOLOGY; HUMANS; INSULIN; LYMPHOCYTES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROTONS; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 18644368869     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00617-0     Document Type: Article

References (27)

1. Cook D.L., Hales C.N. Nature. 311:1984;271.
2. Standen N.B., Quayle J.M., Davies N.W., Brayden J.E., Huang Y., Nelson M.T. Science. 245:1989;177.
3. Noma A. Nature. 305:1983;147.
4. Quast U. Naunyn-Schmiedebergs Arch. Pharmacol. 354:1996;213.
5. Bernadi H., Fosset M., Lazdunski M. Proc. Natl. Acad. Sci. U.S.A. 85:1988;9816.
6. Aguilar-Bryan L., Bryan J., Nakazaki M. Recent Prog. Horm. Res. 56:2001;47.
7. Wollheim C.B., Sharp G.W.G. Physiol. Rev. 61:1981;914.
8. (a) For recent reviews see: Bryan J., Aguilar-Bryan L. Biochimica et Biophysica Acta. 1461:1999;285.
9. (b) Seino S., Miki T., Yano H. Endocrine Updates. 11:2001;91.
10. © Ashcroft S.J.H. J. Membr. Biol. 176:2000;187.
11. Gribble F.M., Ashcroft F.M. Metab., Clin. Exp. 49:2000;3.
12. Newgreen D.T., Bray K.M., McHarg A.D., Weston A.H., Duty S., Brown B.S., Kay P.B., Edwards G., Longmore J., Southerton J.S. Br. J. Pharmacol. 100:1990;605.
13. Escande D., Thuringer D., Leguern S., Cavero I. Biochem. Biophys. Res. Commun. 154:1988;620.
14. Yokoshiki H., Sunagawa M., Seki T., Sperelakis N. Am. J. Physiol. 274:1998;C25.
15. Garrino M.G., Plant T.D., Henquin J.C. Br. J. Pharmacol. 98:1989;957.
16. (a) Greenwood R.H., Mahler R.F., Hales C.N. Lancet. 28:1976;444.
17. (b) Bjork E., Berne C., Kampe O., Wibell L., Oskarsson P., Karlsson F.A. Diabetes. 45:1996;1427.
18. Alemzadeh R., Langley G., Upchurch L., Smith P., Slonim A.E. J. Clin. Endocrinol. Metab. 83:1998;1911.
19. Gilman A.G., Goodman L.S., Rall T.W., Murad F. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 1985;7th; Macmillam, New York. p 799.
20. (a) Lebrun P., Arkhammar P., Antoine Q.-A., Hansen J.B., Pirotte B. Diabetologia. 43:2000;723.
21. (b) De Tullio P., Pirotte B., Lebrun P., Fontaine J., Dupont L., Antoine M.-H., Ouedraogo R., Khelili S., Maggetto C., Masereel B., Diouf O., Podona T., Delarge J. J. Med. Chem. 39:1996;937.
22. Gribble F.M., Ashfield R., Ammala C., Ashcroft F.M. J. Physiol. 498:1997;87.
23. Pirotte, B.; Lebrun, P.; De Tullio, P.; Somers, F.; Delarge, J.; Hansen, J. B.; Nielsen, F. E.; Hansen, H. C.; Mogensen, J. P.; Tagmose T. M. WO 9749692.
24. 1H NMR and LC/MS) consistent with the reported structures and compound purity was determined to be >95%.
25. Somers F., De Tullio P., Boverie S., Dogne J.M., De Leval X., Antoine M.-H., Lebrun P., Pirotte B. Pharm. Pharmacol. Commun. 6:2000;89.
26. De Tullio, P.; Nielsen, F. E.; Hansen, J. B.; Hansen, H. C.; Pirotte, B.; Boverie, S.; Somers, F.; Lebrun, P.; Mogensen, J. P. WO 9932467.
27. Hansch C., Leo A., Unger S.H., Kim K.H., Nikaitani D., Lien E.J. J. Med. Chem. 16:1973;1207.